PT  - JOURNAL ARTICLE
AU  - Zhuang, Qian
AU  - Zheng, Xiaoxiao
AU  - Yao, Shuxia
AU  - Zhao, Weihua
AU  - Becker, Benjamin
AU  - Xu, Xiaolei
AU  - Kendrick, Keith M.
TI  - Oral, similar to intranasal, administration of oxytocin decreases top-down social attention, but additionally enhances bottom-up control
AID  - 10.1101/2021.09.20.21263870
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.09.20.21263870
4099  - http://medrxiv.org/content/early/2021/09/26/2021.09.20.21263870.short
4100  - http://medrxiv.org/content/early/2021/09/26/2021.09.20.21263870.full
AB  - The neuropeptide oxytocin (OXT) can modulate social cognition by facilitating attention towards social cues and may be a potential therapeutic intervention for social attention impairment in disorders such as autism. Intranasal administration of OXT is widely used to examine its functional effects in both adults and children. However, we have recently shown that administration orally as a lingual spray also modulates neural responses to emotional faces and is potentially better tolerated for therapeutic use. Here, we therefore examined if 24IU OXT administered orally is also effective in facilitating social attention. In a randomized, placebo-controlled, pharmacological study we used a validated emotional anti-saccade eye-tracking paradigm to explore effects of oral OXT on bottom-up and top-down attention processing in 80 healthy male subjects. Our findings showed in terms of top-down attention, oral OXT increased both errors and response latencies for all social stimuli (angry, fearful, happy, sad and neutral emotion faces) but not non-social stimuli (oval shape) in the anti-saccade condition. Comparison with our previous intranasal OXT study using the same task paradigm revealed both routes have a similar effect on increasing anti-saccade errors. However, compared with intranasal OXT, oral OXT significantly decreased error rates for social stimuli in the pro-saccade condition, indicative of increased bottom-up attention processing. Additionally, OXT administration both either route produced an anxiolytic effect evidenced by reduced state anxiety scores. Together, these findings suggest that orally administered OXT has a similar effect on top-down social attention control and anxiety as intranasal administration but more potently influences bottom-up control.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialClinicalTrials.gov ID:NCT04493515;NCT04815395Funding StatementThis work was supported by the National Natural Science Foundation of China (grant numbers 31530032,KMK and 91632117,BB), Key Technological Projects of Guangdong Province (grant number 2018B030335001,KMK).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The current study was approved by the local ethics committee of University of Electronic Science and Technology of China (UESTC).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data in the manuscript could be accessible from authors on the request